Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-06-03

Clinical Trial Results: Otoprotection With SPI-1005 for Prevention of Temporary Auditory Threshold Shift [Phase 2]

View source ↗

Summary

Phase 2 trial results evaluating SPI-1005 for prevention of temporary auditory threshold shift (otoprotection) show the study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SPI-1005

Snippet

Sponsor: Sound Pharmaceuticals, Incorporated | Conditions: Temporary Auditory Threshold Shift | Phase 2 | Status: COMPLETED | Results posted: 2026-06-03